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Introduction 22
The link between hyperglycaemia and adverse reproductive outcomes has been 23 extensively and well documented (Miller et al. 1981; Combs and Kitzmiller, 1991; Greene, 24 1999; McCance 2011; Simmons, 2011) . Despite recent advances in therapeutic 25 management there are still markedly greater rates of complications in pregnancies 26 accompanied by hyperglycaemia, rather than normoglycaemia (Metzger et al. 2007 ; 27 Kitzmiller et al. 2008; Shand et al. 2008; Ali and Dornhorst, 2011) . The periconception 28 period has recently emerged as a period of acute sensitivity to changes in the maternal 29 metabolic environment. Negative effects of periconceptional maternal hyperglycaemia, 30 diabetes and obesity on the developing oocyte and preimplantation embryo have been 31 described, with consequences for pregnancy success, fetal development and postnatal 32 outcomes (Jungheim and Moley 2008; Minge et al. 2008; Wyman et al. 2008; Jungheim 33 2010; Ramin et al 2010; Wang and Moley 2010; Cardozo et al. 2011; Fleming et al. 34 2012) . 35 36 Glucosamine (GlcN), the simple amino sugar, has been documented to upregulate the 37 hexosamine biosynthesis pathway, as it is converted to GlcN-6-phosphate, an 38 intermediate of the pathway that bypasses the rate limiting glutamine-fructose-6-39 phosphate amidotransferase enzyme (GFAT) (Marshall et al. 1991; McClain and Crook, 40 1996) . In somatic tissues, elevated flux through the hexosamine pathway has been 41 associated with perturbed health states, including insulin resistance (Marshall et al. 1991; 42 Patti et al. 1999; McClain 2002; Buse 2006; Teo et al. 2010) . Previous studies have 43 demonstrated that exposure of murine, bovine and porcine cumulus-oocyte complexes 44 (COCs) to GlcN during in vitro maturation significantly reduces subsequent embryo 45 developmental competence (Sutton-McDowall et al. 2006; Kimura et al. 2008; Schelbach 46 et al. 2010) . Similarly, GlcN addition during murine embryo culture impairs blastocyst 47 development (Pantaleon et al. 2010) , while addition of GlcN to bovine embryo culture, 48 from the 8-cell stage, decreases the development rate of embryos and skews the sex 49 ratio towards males (Kimura et al. 2008) . During maturation of the COC, significant 50 glucose flux through the hexosamine biosynthesis pathway supports expansion of the 51 cumulus matrix (Sutton-McDowall et al. 2004) , as UDP-N-acetyl glucosamine, the end 52 product of the pathway, is the substrate for hyaluronic acid synthesis. However, UDP-53 acetyl glucosamine also serves as the substrate for O-linked glycosylation of serine and 54 threonine residues in a range of proteins (Torres and Hart 1984) . Hyperglycaemic 55 disruption of cellular function is thought to be mediated through increased levels of O-56 linked glycosylation and altered function of key proteins as a result of upregulated 57 (Specialty Feeds, Glen Forrest, Australia) (Table 1) . Twelve mice were allocated per 124 treatment group and eight replicate experiments were performed (total of 96 mice per 125 dietary group). Mouse weights were recorded weekly. 126
Plasma insulin and glucose tolerance 127
Blood samples were collected following 7, 10 and 11 weeks of dietary manipulation. Mice 128 were fasted overnight and 400 -600 µl blood was collected from anaesthetised mice via 129 an orbital bleed. Blood was centrifuged for 10 min at 4 o C, and plasma was collected and 130 stored at -20˚C. Plasma insulin levels were measured in duplicate using a Rat Insulin RIA 131
Kit (LINCO Research, Inc., St. Charles, MO, USA), with a sensitivity of 0.1 ng/ml and an 132 intra-assay coefficient of 1.4 -4.6 %. Samples were collected from six mice per dietary 133 group from two replicates, giving a total of 12 mice per dietary group. 134
Following blood collection at 10 weeks of dietary intervention, mice were allowed to 135 recover from the anaesthesia for one hour. An intraperitoneal glucose tolerance test was 136 then performed. Mice were injected intraperitoneally with 1 g D-glucose/kg bodyweight. 137
Blood samples were collected by nicking of the tail vein, and blood glucose was 138 measured using an Accu-Check® Advantage Glucometer at 0, 15, 30, 60, 90 and 120 139 minutes post-glucose injection. Glucose tolerance was assessed by calculating area 140 under the glucose curve (Le Floch et al. 1990) . 141
GlcN treatment 142
Following 11 weeks of dietary manipulation, mice were weighed and randomly assigned 143 to receive either 0 or 20 mg/kg GlcN. This resulted in four treatment groups 1) LF -GlcN, 144
2) LF + GlcN, 3) HF -GlcN and 4) HF + GlcN with 48 mice per group. The average 145 weight of all mice that had been on the low fat diet was used to determine the volume of a 146 4 mg/kg GlcN solution to correspond to a 20 mg/kg dose (i.e. 5 l per kg bodyweight). 147
This standardized volume was administered to all GlcN-treated mice in the LF and HF 148 dietary groups, to avoid significant variation in total dosage due to different body weights. 149
An equivalent volume of PBS was administered to control animals in LF and HF groups. 150
Mice were injected with GlcN as described in Experiment 1, with the exception that 151 females were placed with males for a maximum of 2 nights. Hence, mice in Experiment 2 152 were treated for 4-5 days with GlcN. Mice were maintained on their assigned LF or HF 153 diets throughout pregnancy. 154
To determine whether GlcN treatment influenced glucose tolerance, mice that did not 155 mate after two attempts were fasted overnight on the day of the final (fifth) GlcN injection. 156
Fasting blood samples were collected and glucose tolerance tests were performed as 157 described above. 158
Pregnancy outcomes 159
Fetal and placental outcomes were assessed according to the methods described for 160 Experiment 1. In addition, placental length and width were recorded to determine 161 placental volume. Ovaries were also removed and corpora lutea (CL) numbers were 162 counted as an indication of ovulation rate. 1 and 2 ). An equivalent volume of PBS was 177 administered to control animals (0 mg/kg GlcN) in each of the age groups. Mice received 178 injections of PBS or GlcN for a minimum of 4 and a maximum of 7 days as described in 179 Experiment 1. Pregnancy outcomes were assessed at day 18 gestation as described for 180
Experiment 2. 181

Statistics 182
Statistical analysis was performed with SAS (Statistical Analysis Software) version 9.2. 183
Chi-squared analyses were performed for parameters relating to mating (n, %), 184 pregnancy (n, %), viable day 18 fetuses (%), resorptions from implantations (%), fetuses 185 with abnormalities (n, %) and pregnancies with abnormal fetuses (n, % 
Pregnancy rates 202
GlcN treatment did not affect the number or proportion of mice that mated, as indicated by 203 the presence of a sperm plug. Similarly, there were no differences between treatment 204 groups in the number of mice that were pregnant on day 18, or the proportion of mice that 205
were pregnant relative to those that successfully mated (Table 2) . 206
Litter size 207
Regardless of dose administered, GlcN treatment reduced the number of implantations 208
and litter size (number of viable fetuses) at day 18 gestation (P < 0.05). The number of 209 resorptions detected at day 18 pregnancy was not altered by GlcN treatment, but when 210 expressed as a percentage of implantations, resorption rate was increased by GlcN 211 treatment, regardless of dose (Table 2) . 212
Fetal outcomes 213
Periconception GlcN treatment did not alter fetal weight or length of the viable fetuses at 214 day 18 of pregnancy (Table 2 ) but tended to increase placental weight (P = 0.08). Birth 215 defects, as determined by gross morphological appearance on day 18 gestation were not 216 associated with any treatment. A single fetus presented with one very small eye in the 217 control group, and another fetus had an abdominal hernia in the GlcN 20 mg/kg group. 218
Experiment 2: Periconception GlcN treatment in mice maintained on different fat content 219
diets. 220
Effects of dietary manipulation on bodyweight and glucose tolerance prior to GlcN 221 administration 222
Female mice maintained on the HF diet were heavier than their LF counterparts from5 223 weeks of dietary manipulation (LF diet: 21.1 ± 0.2 g (n=96); HF diet: 23.6 ± 0.3 g (n=96)) 224 (P < 0.05). The weight difference increased, such that mice fed the HF diet were 22% 225 heavier than the LF fed group by the time of mating at 11 weeks of dietary exposure (LF 226 diet: 24.8 ± 0.3 g (n=96); HF diet: 30.5 ± 0.4 g (n=96)) (P < 0.05)). 227
After ten weeks of high fat feeding, there was no significant difference in glucose 228 tolerance, assessed as glucose area under the curve, for mice on the LF and HF diets (LF 229 diet: 2402 ± 154 mM/ 120 min (N=12); HF diet: 2663 ± 124 mM/ 120 min (N=12)). There 230 were also no differences detected in plasma insulin levels for mice maintained on the two 231 diets at either 7 weeks (LF: 0.26 ± 0.06 ng/ml (n=10), HF: 0.23 ± 0.04 ng/ml (n=7)), 9 232 weeks (LF: 0.22 ± 0.04 ng/ml (n=9), HF: 0.24 ± 0.04 ng/ml (n=9)) or 10 weeks (LF: 0.28 ± 233 0.09 ng/ml (n=8), HF: 0.30 ± 0.08 ng/ml (n=9)) of dietary exposure. Insulin levels were 234 measured in 12 mice from each dietary group at each time point, and were below the 235 levels of detection for the assay (0.1 ng/ml) in 2-5 mice per group. 236
Glucose tolerance following GlcN administration 237
Glucose area under the curve in a glucose tolerance test, in non-pregnant mice, was not 238 altered by 5 days GlcN treatment and did not differ between dietary groups (mM/ 120 min) 239 (LF -GlcN: 2893 ± 95 (n = 10), LF + GlcN: 2807 ± 128 (n = 12), HF -GlcN: 3005 ± 112 240 (n = 12), HF + GlcN: 3080 ± 128 (n = 12)). 241
Pregnancy rates 242
Mice in this experiment were placed with males for a maximum of 2 nights, resulting in 243 lower proportions mating when compared to Experiments 1 or 3. GlcN treatment did not 244 affect the number or proportion of mice that mated. However, more LF mice that were 245 treated with GlcN became pregnant than those maintained on a LF diet and not given 246 GlcN (P < 0.05) ( Table 3 ). In addition, less GlcN treated HF fed mice became pregnant 247 after mating, when compared to GlcN treated LF fed mice, or when compared to HF fed 248 mice that were not treated with GlcN (P < 0.05) ( Table 3) . 249
Litter size 250
Implantation number, litter size and resorption rates at day 18 of pregnancy were not 251 affected by GlcN treatment or high fat feeding (Table 3) . Ovulation rate, as indicated by 252 the number of corpora lutea present at day 18 gestation, was also not affected by any 253 treatment (Table 3) . 254
Fetal outcomes 255
Fetal weight at day 18 of pregnancy was reduced by maternal high fat feeding (P < 0.05, 256 Table 4 ). Periconceptional exposure to GlcN also reduced fetal weight (P < 0.05, Table 4 ). 257
Although there was no significant interaction between the two factors, fetal weight was 258 reduced by GlcN only in LF-fed mice. Exposure to a HF maternal diet also reduced fetal 259 length (P < 0.05, Table 4), while periconception GlcN exposure did not affect fetal length 260 (Table 4) . Placental weight did not differ between treatment groups (Table 4) . Placental 261 volume tended to be reduced in mothers fed a HF diet (P = 0.08), but there were no 262 differences in placental volume between GlcN treatment groups (Table 4) . 263
An increased number (P < 0.001) and proportion (P < 0.01) of fetuses presented with 264 congenital abnormalities in the LF + GlcN group, when compared to all other groups 265 (Table 4) . Similarly, the number (P < 0.01) and proportion (P < 0.001) of pregnancies 266 containing a fetus with abnormalities was higher for the LF + GlcN group relative to all 267 others (Table 4 ). The proportion of mothers that carried birth-defected fetuses was also 268 increased by exposure to a HF diet, irrespective of GlcN treatment, when compared to the 269 LF -GlcN group (Table 4 ). The majority of abnormalities were eye defects (LF+GlcN: 270 n=14/17 fetuses; HF-GlcN: n=3/4 fetuses; HF+GlcN: n=2/3 fetuses), characterised by 271 missing one or both eyes or having underdeveloped eyes. Identification of defects was 272 performed by gross examination only, no further histopathological analysis of the 273 ophthalmic defects was performed. An abdominal omphalocele was present in 3 fetuses 274 from the LF + GlcN group, and 1 fetus from each of the HF -GlcN and HF + GlcN groups. 275
Experiment 3: Periconception GlcN treatment of 8 and 16 week old mice. 276
Because different effects of GlcN treatment were observed in mice fed the control mouse 277 chow diet between Experiments 1 and 2, we decided to investigate the effect of maternal 278 age at periconceptual GlcN administration (8 wk vs. 16 wk) on reproductive outcomes, as 279 this was the only major difference between the experimental groups. Older mice were 280 heavier than younger mice for the 3 weeks they were housed prior to GlcN treatment 281 (bodyweight at mating at 8 wk: 22.1 ± 0.2 g (n=24); bodyweight at mating at 16 wk: 25.0 ± 282 0.4 g (n=24) (P < 0.05)). 283
Pregnancy rates 284
GlcN treatment and maternal age did not affect the number or proportion of mice that 285 mated or became pregnant (Table 5) . Significantly more mice mated over the first 2 days 286 compared to the third and fourth days (data not shown, P < 0.0001). 287
Litter size 288
An interaction effect was detected between GlcN and maternal age for the number of 289 implantations and litter size (P < 0.01 for both), where GlcN administration in 8 wk old 290 mice reduced implantations and litter size, but not in 16 wk old mice (GlcN x age 291 interaction, P < 0.01 for both) (Table 5 ). Implantation number tended to be reduced by 292
GlcN in 16 wk old mice, when compared to 16 wk mice that did not receive GlcN, but this 293 was not significant. Older mice that were not treated with GlcN had higher implantation 294 rates and litter sizes than young mice (P < 0.01) ( Table 5) . 295
Overall, the total number of implantations (P < 0.0001) and viable fetuses (P < 0.0001) 296 was lowest in the 8 wk + GlcN group. No differences in the number of resorptions were 297 seen between the four groups (Table 5) , however, a greater proportion of implantations 298 resorbed (P < 0.05) in 8 wk old GlcN treated mice (Table 5) . Mean ovulation rate, as 299 determined by CL number, tended to be decreased in young mice that received 20 mg/kg 300 GlcN, although this was not significant (P = 0.076) ( Table 5) . 301
Fetal outcomes 302
Maternal age did not independently influence fetal weight whereas GlcN was found to 303 have a significant effect on fetal weight (P < 0.05), and there was a significant interaction 304 between GlcN and maternal age (P < 0.01). Fetal weight was reduced by periconception 305
GlcN treatment in 16 wk old mice (P < 0.05) (Table 6 ), while the same treatment did not 306 affect fetal weight in 8 wk old mice. 307
GlcN reduced fetal length in pups derived from 16 wk old GlcN treated mice (P < 0.05) 308 (Table 6 ). For fetal length, a significant interaction was observed between GlcN and 309 maternal age (P < 0.04), that was lost when maternal weight was included in the analysis 310 as a co-variate, suggesting that maternal weight may be a contributing component to age-311 associated changes in fetal size. 312
Placental weight was increased in 8 wk old mice treated with GlcN, when compared to all 313 other groups (P < 0.05, Table 6 ). There was no effect of maternal age on placental 314 weight. No differences were detected in placental volumes between the 4 groups ( Table  315 6). 316
A significantly higher number of abnormal fetuses were present in litters of 16 wk old GlcN 317 treated mice, compared to all other groups (P < 0.05, Table 6 ). A higher number, and 318 proportion, of GlcN treated older mice had pregnancies characterized by at least one 319 abnormally developing fetus, when compared to the remaining groups (P < 0.05, Table 6 ). 320
Birth defects were again characterised by eye defects (8 wk -GlcN, n=2 fetuses; 16 wk -321 GlcN, n=3 fetuses; 16 wk + GlcN, n=7 fetuses). One fetus in the 16 wk + GlcN group 322 presented with an omphalocele. 323
Discussion 325
Previous studies have demonstrated that in vitro exposure of the developing oocyte or 326 preimplantation embryo to glucosamine has detrimental consequences for subsequent 327 embryo development (Sutton-McDowall et al. 2006; Kimura et al. 2008; Pantaleon et al. 328 2010; Schelbach et al. 2010) . Furthermore, subcutaneous administration of 40 mg 329 (~1600-2000 mg/kg) glucosamine to pregnant mice on day 7.5 days of gestation is 330 associated with an increased incidence of neural tube defects (Horal et al. 2004 ). The 331 current study has extended these observations by demonstrating adverse effects of in 332 vivo glucosamine administration during the periconception period on subsequent murine 333 embryonic and fetal development.
These effects were manifested as reduced 334 implantation rates, retarded fetal development and an increased incidence of congenital 335 malformations, with the occurrence of these perturbations being influenced by 336 accompanying maternal conditions. 337
Maternal age, in particular, was shown to influence the effects of periconceptional 338 glucosamine on reproductive outcomes. Glucosamine treatment reduced litter size in 339 young, 8-week old mice. The decrease in litter size was mediated in part by a reduction in 340 mean implantation rate as well as an increase in the proportion of implantations that 341 resorbed. In contrast, in older, adult mice (16 weeks of age), periconception glucosamine 342 did not alter litter size, but reduced fetal weight and increased the incidence of congenital 343 abnormalities. Furthermore, periconceptional glucosamine increased placental weight in 344 8-week, but not 16-week old, mice. 345
Mechanisms involved in the generation of divergent reproductive outcomes as a result of 346 exposure to periconception glucosamine in different aged mice are unclear and require 347 further investigation. In younger mice, implantation rate was decreased. Reduced litter 348 size and the observed increase in placental weight may have contributed to maintenance 349 of fetal size in glucosamine treated young mice. While implantation rates were not altered 350 in older mice, reduced fetal weight and an increased incidence of birth defects does 351 suggest that oocyte or embryo quality has been affected by glucosamine exposure at both 352 ages, but with differing consequences for subsequent development. The periconception 353 glucosamine treatment protocol used in the current study may potentially affect the 354 preovulatory, ovulated or fertilizing oocyte, the early embryo or the uterine environment 355 and receptivity. No significant difference in ovarian corpora lutea numbers suggests that 356 the reduction in litter size in young mice is not due to fewer oocytes being ovulated. Body 357 weight is higher in adult, compared to young mice, but body composition was not 358 assessed in the current study. Whether changes in adiposity or metabolic indices could 359 have influenced the metabolism or actions of glucosamine at different ages is unclear. 360 Body weight differences would result in a minor difference in total glucosamine dose 361 administered on a per kg body weight basis, however, adverse effects were observed in 362 the young mice, that would have received the lower total dose. Age related changes in 363 activity of the hexosamine signalling pathway have been suggested; with one study 364 reporting an increase in hexosamine biosynthesis pathway activity in aged rats (Einstein 365 et al. 2008) , while others report reductions in skeletal muscle activity of the GFAT enzyme 366 and reduced levels of O-linked N-acetyl glucosamine (O-GlcNac) and O-GlcNAc 367 transferase (OGT) in heart in mice and rats, across a similar age span to that assessed in 368 the current study (Buse et al. 1997; Fulop et al. 2007) . Previous in vitro studies have 369 supported a role for glucosamine induced increases in flux through the hexosamine 370 biosynthesis pathway, and an associated increase in O-linked glycosylation in the 371 cumulus-oocyte-complex or early embryo, in mediating the adverse effects of 372 glucosamine (Pantaleon et al. 2010; Schelbach et al. 2010) . Further studies are required 373 to assess the specific mechanisms through which short-term, periconceptional 374 glucosamine administration is affecting oocyte and embryo developmental competence in 375 vivo, including assessment of the hexosamine biosynthesis pathway and O-linked 376 glycosylation, and to more fully characterise the interaction with maternal age. 377
The metabolic perturbations accompanying diabetes and obesity are associated with 378 upregulation of the hexosamine biosynthesis pathway (Robinson et al. 1995; Buse et al. 379 1997; Considine et al. 2000; Veerababu et al. 2000 , Kaneto et al. 2001 McClain 2002 ) 380 and both conditions are associated with an increased incidence of adverse pregnancy 381 outcomes, including miscarriage, congenital abnormalities and altered fetal growth (Miller 382 et al. 1981; Combs and Kitzmiller 1991; Greene 1999; Stothard et al. 2009; Simmons, 383 2011) . Studies have demonstrated negative effects of exposing the developing oocyte or 384 embryo to maternal hyperglycaemia in vivo or in vitro (Diamond et al. 1989; Moley et al. 385 1991; Wyman et al. 2008; Jungheim and Moley 2008; Wang et al. 2009; Ramin et al. 386 2010; Wang and Moley 2010) and improved glycemic control during the pre-and early 387 pregnancy period in women with diabetes has been associated with reduced incidence of 388 miscarriage and risk for fetal abnormalities (Ray et al. 2001; Temple et al. 2006) . 389
Furthermore, embryos collected at the one-cell stage from diabetic mice, and transferred 390 to normoglycemic recipients, have an increased incidence of retarded fetal growth and 391 fetal abnormalities (Wyman et al. 2008) , providing clear evidence that exposure to 392 perturbed maternal glucose metabolism during the periconceptional period can affect 393 subsequent fetal development. 394
In the current study, we therefore further assessed the effects of periconception 395 glucosamine in overweight mice that had been maintained on a high fat diet, to assess 396 glucosamine effects under perturbed metabolic conditions which may be associated with 397 upregulation of the hexosamine pathway. Increased fasting serum insulin, glucose and 398 free fatty acids, and increased adipose tissue weight, have previously been reported 399 following 16 weeks exposure to the same high fat diet used in the present study (Minge et 400 al. 2008) . However, high fat fed mice in the current study did not demonstrate differences 401 in glucose tolerance or fasting insulin, following 11 weeks dietary intervention, suggesting 402 that longer dietary exposure may have been required to induce detectable impairments in 403 insulin and glucose metabolism. Specific assessment of insulin sensitivity may have also 404 been required to more fully characterise the effects. Nevertheless, fat fed mice were 405 overweight suggesting that some degree of metabolic perturbation did occur and the 406 observed effects of the high fat diet on fetal size support this. Litter size was not altered in 407 high fat fed mice, however, in agreement with previous studies, feeding a high fat diet 408 before and throughout pregnancy reduced fetal weight and length , 409 irrespective of glucosamine treatment. These findings extend a previous study reporting 410 adverse effects of this diet on blastocyst development (Minge et al. 2008) . 411
Periconception glucosamine treatment reduced fetal weight in 16 week old mice fed 412 control chow; however, no additive effects of glucosamine treatment and high fat feeding 413 on reproductive outcomes were observed. Other studies have reported that glucosamine 414 administration, or upregulation of the hexosamine biosynthesis pathway through 415 overexpression of the GFAT enzyme, does not potentiate high fat feeding induced insulin 416 resistance in rats or mice (Barrientos et al. 2010; Cooksey and McClain 2010) , suggesting 417 a potential for maximal upregulation of the pathway. The lack of additive effects may also 418 implicate a role for the hexosamine biosynthesis pathway in mediating the negative 419 effects of periconception high fat diets on oocyte and embryo competence, however, 420 specific analyses of hexosamine biosynthesis pathway activity and its downstream 421 effectors in reproductive tissues from obese mice are required to assess this further. 422
Animal studies have demonstrated reductions in insulin sensitivity following intravenous 423 administration of glucosamine (Rossetti et al. 1995; Virkamaki et al. 1997; Patti et al. 424 1999; Stampinato et al. 2003) . Despite some studies suggesting similar effects in 425 humans, systematic reviews of clinical studies have identified limited evidence for an 426 effect of oral glucosamine on insulin sensitivity or glucose tolerance in human subjects, 427 but acknowledge the need for further study in subjects with existing risk of impaired 428 glucose metabolism (Anderson et al. 2005; Dostrovosky et al. 2011; Simon et al. 2011) . 429
The current study did not detect any differences in glucose tolerance in non-pregnant 430 mice following 5 days of intraperitoneal glucosamine administration, but insulin sensitivity 431 was not assessed. Nevertheless, despite the lack of measurable effects of acute 432 glucosamine administration on glucose or insulin levels, effects of glucosamine on 433 reproductive outcomes were observed, suggesting that the effects of short-term 434 glucosamine have occurred independent of measurable metabolic perturbations. 435
In mice, in vivo uptake of radiolabelled glucosamine has been detected in follicular fluid, 436 and cells of the ovarian follicle, suggesting that glucosamine is not metabolised 437 exclusively externally to the reproductive system, and indicating the potential for tissue 438 specific effects, distinct from peripheral metabolic effects (Fowler and Guttridge 1987; 439 Fowler 1988; Fowler and Barrett 1989; Horal et al. 2004) . Bioavailability of GlcN is 440 dependent upon its route of administration (Aghazadeh-Habashi et al. 2002) . 441
Intraperitoneally injected GlcN has been shown to have complete bioavailability, 442 resembling intravenous administration (Aghazadeh-Habashi et al. 2002) , while 443 bioavailability of orally administered glucosamine is low (Setnikar et al. 1993; Adebowale 444 et al. 2002; Aghazadeh-Habashi et al. 2002; Persiani et al. 2005) , Intraperitoneal 445 injection of glucosamine in the current study allowed administration of a consistent, 446 bioavailable glucosamine dose. However, while the dose of 20 mg/kg (0.5 mg in a 25 g 447 mouse) used in this study resembles the commonly recommended oral dose of 1500 mg 448 in an adult human, differences in the route of administration may result in a higher 449 bioavailable dosage in this study. Nevertheless, in contrast to a previous study reporting 450 adverse effects of postimplantation treatment with high doses of glucosamine (Horal et al. 451 2004), the current study has utilised treatment within a physiologically relevant range. 452
Periconceptional glucosamine treatment was associated with an increase in placental 453 weight in young mice. The effects of maternal metabolic perturbation on placental 454 development are complex and dependent on the timing and nature of the perturbation. 455
For example, feeding mice a diet high in fat and sugar throughout pregnancy reduces 456 fetal and placental weight (Vaughan et al. 2012) , while no effect on placental weight, but 457 an increase in fetal weight, has been reported in high fat fed mice (Jones et al. 2009) . 458
Transient hyperglycaemia in early-mid gestation in the rat (day 10) has been reported to 459 increase placental weight (Ericsson et al. 2007) . However, studies assessing the effects 460 of periconceptional metabolic perturbations (eg. Wyman et al. 2008) have generally not 461 reported on placental outcomes. Further assessment of placental structure and nutrient 462 transport capacity would be required to determine whether increased placental weight in 463 glucosamine treated young mice was associated with altered function. Similarly, fetal 464 weight was reduced, while placental size was unaffected, in mice fed high fat diets 465 throughout pregnancy in the current study. Whether altered placental structure or 466 function contributed to reduced fetal growth in fat-fed mice requires further analysis. 467
Abnormalities observed following exposure of oocytes and preimplantation embryos to 468 hyperglycaemia included neural tube defects, limb deformities and growth retardation 469 (Wyman et al. 2008) . Similarly, common malformations associated with diabetic 470 pregnancies are heart, neural tube and caudal defects (Salbaum and Kappen 2011) . The 471 defects observed in the current study did differ, with primarily ocular defects, and some 472 incidences of fetal omphalocele. Preconception obesity has been associated with an 473 increased risk of fetal omphalocele (Waller et al. 2007 ) and glucose transporter-1 deficient 474 mice exhibit increased rates of microphthalmia, suggesting that metabolic perturbations 475 could contribute to the abnormalities. The strain of mice (C57Bl/6) used in this study do 476 have an increased susceptibility to ophthalmic defects (Sulik et al. 1981; Parnell et al. 477 2006) . However, acute alcohol exposure in early gestation increases the incidence of 478 ocular defects in offspring of these mice, suggesting that perturbations during embryonic 479 development can increase the risk (Sulik et al. 1981; Parnell et al. 2006) . 480
Advanced maternal age (Hansen 1986; Friede et al. 1988; Nybo Andersen et al. 2000; 481 Miletic et al. 2002; Hsieh et al. 2010) reproductive success rates. The increasing rate of pregnancy in older women (Martin et 484 al. 2006 , Chan et al. 2009 ) and the increasing incidence of metabolic disorders involving 485 perturbed glucose metabolism (Dunstan et al. 2002; Colagiuri et al. 2005; Wang et al. 486 2011) , suggests that the potential for interactive effects should be considered. Studies 487 that have considered the effects of intercurrent illness on adverse perinatal outcomes in 488 older women, to date, have suggested that the effects of older age are independent of 489 any existing diabetes (Jacobsson et al. 2004; Delbaere et al. 2007) . Nevertheless the 490 observation that reproductive outcomes were perturbed in adult mice of an age well within 491 the reproductively fit range in combination with a metabolic perturbation that did not result 492 in measurable differences in glucose metabolism, suggests that the potential for 493 interaction should be considered. 494
Conclusion 495
Collectively these results demonstrate that in vivo, periconception glucosamine exposure 496 in mice elicits detrimental effects upon fetal development that are dependent on maternal 497 age. Adverse effects of increased maternal weight, induced by high fat feeding, on fetal 498 development were also confirmed, but these effects were not exacerbated by 499 glucosamine treatment. The specific effects at a cellular level that contribute to altered 500 reproductive outcomes associated with acute periconception glucosamine exposure 501 require further study. Given that hyperglycemia elicits effects by stimulating divergent 502 pathways, glucosamine may prove to be a useful tool to study the specific effects of this 503 signalling pathway in glucose induced pathophysiologies and for further analysing 504 associations between age and hyperglycemia. Previous studies have suggested 505 dysregulation of the hexosamine biosynthesis pathway as a potential mechanism through 506 which maternal hyperglycaemia elicits effects on oocyte and preimplantation embryo 507 development (Schelbach et al. 2010; Pantaleon et al. 2010) . The current study, suggests 508 that further studies should assess the potential role of increased activity of the 509 hexosamine biosynthesis pathway, and associated effects such as increased O-linked 510 glycosylation, in contributing to the in vivo effects of periconceptional maternal 511 hyperglycaemia. 512 Implantations represents the mean number of implantation sites (sum of viable and nonviable fetuses and resorption sites) detected per mouse at day 18 gestation. Litter size represents the number of viable fetuses at day 18 gestation. Fetal and placental data represent n=74 (0 mg/kg), n=38 (20 mg/kg) and n=36 (400 mg/kg). Data presented as mean ± sem. Values with different superscripts are significantly different, P < 0.05. 
